Moderna fell in trading on Thursday after its vaccine revenues missed analysts’ expectations and the company made a small increase in product sales projections for the year.
While Moderna recorded its first profitable quarter, revenues of $1.94bn came in below Wall Street expectations. The 4.3% increase in projected annual product sales to $19.2bn pales in comparison to the $26bn that rival Pfizer now expects from Covid vaccine sales this year.
The final count depends on the mix of primary two-dose vaccine and booster shots that use less vaccine material.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: